Wikisage, the free encyclopedia of the second generation, is digital heritage
Molnupiravir: Difference between revisions
(→Source) |
(→Source) |
||
| Line 9: | Line 9: | ||
==Source== | ==Source== | ||
[https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)] | [https://enwiki.miraheze.org/w/index.php?title=Molnupiravir&oldid=2390 enWiki(Miraheze)] | ||
[[d:Q96376832]] | [[d:Q96376832]] | ||
Revision as of 14:06, 27 January 2021
Molnupiravir (development codes EIDD-2801 and MK-4482) is an investigational antiviral drug for oral administration for the treatment of influenza. It is an N4-hydroxycytidine-donating prodrug, a nucleoside derivative known to be mutagenic that acts against RNA viruses by introducing errors in RNA replication by the viral RNA-dependent RNA polymerase. It also has some activity against coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-25, responsible for SARS, MERS and COVID-19 respectively. It was developed at Emory University in Atlanta, Georgia, before being acquired by Ridgeback Biotherapeutics in Miami, Florida, which has partnered with Merck & Co. for further development. [1]
External Links
Coronavirus RNA Proofreading Molecular basis and therapeutic target